Polycystic ovary syndrome and excessive body weight impact independently and synergically on fertility treatment outcomes.

Publisher: BioMed Central Country of Publication: England NLM ID: 101153627 Publication Model: Electronic Cited Medium: Internet ISSN: 1477-7827 (Electronic) Linking ISSN: 14777827 NLM ISO Abbreviation: Reprod Biol Endocrinol Subsets: MEDLINE

Original Publication: London : BioMed Central, 2003-

Polycystic Ovary Syndrome*/complications ; Polycystic Ovary Syndrome*/physiopathology ; Polycystic Ovary Syndrome*/blood ; Polycystic Ovary Syndrome*/therapy ; Obesity*/complications ; Obesity*/physiopathology ; Obesity*/blood ; Infertility, Female*/therapy ; Infertility, Female*/etiology ; Overweight*/complications ; Overweight*/physiopathology ; Fertilization in Vitro*; Insulin Resistance/physiology ; Luteinizing Hormone/blood ; Body Weight/physiology ; Humans ; Female ; Adult ; Body Mass Index ; Pregnancy ; Treatment Outcome ; Oocyte Retrieval ; Pregnancy Rate

Background: Polycystic ovary syndrome (PCOS) and obesity can both disrupt reproductive function. However, the extent to which obesity contributes to PCOS manifestations is not very clear. This study aimed to disentangle the relative contributions of PCOS and obesity for reproductive dysfunction in women undergoing in vitro fertilization (IVF).
Methods: A total of 129 women undergoing IVF treatments were recruited. Women were allocated into four groups according to body mass index (BMI) and PCOS diagnosis: normal-weight controls (n = 33; 21.70 ± 1.85 kg/m²), overweight/obesity controls (n = 28; 28.35 ± 3.05 kg/m²), normal-weight PCOS (n = 31; 21.92 ± 1.95 kg/m²), and overweight/obesity PCOS (n = 37; 31.67 ± 5.03 kg/m²). Circulating levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), anti-Müllerian hormone (AMH), glucose and insulin were measured in all groups, while insulin resistance was assessed by the Homeostatic Model (HOMA-IR). Additionally, on the oocyte retrieval day, ∆4-androstenedione, testosterone, progesterone and sex hormone-binding globulin (SHBG), were measured in plasma and follicular fluid (FF). IVF outcomes evaluated included the number of oocytes retrieved, oocyte immaturity, as well as fertilization and blastocyst formation rates. A multivariate analysis was performed to determine the independent effects of PCOS and obesity for reproductive and metabolic parameters.
Results: Women with PCOS presented significantly higher AMH levels, LH: FSH ratio, and lower FF progesterone levels, confirming these as PCOS-specific signatures regardless of BMI. In contrast, women with overweight/obesity had lower plasma and FF SHBG levels and greater HOMA-IR, independently of PCOS. Furthermore, ∆4-androstenedione and testosterone levels in plasma and FF were significantly higher in women with PCOS and overweight/obesity as compared to normal-weight women with PCOS. Despite the higher oocyte retrieval rates in women with PCOS, no differences in oocyte immaturity, fertilization and blastocyst formation rates were observed.
Conclusions: PCOS and obesity independently disrupt female reproductive function suggesting that features associated with each condition may differ. Furthermore, our study shows that obesity exacerbates hyperandrogenism in women with PCOS, highlighting a synergistic detrimental impact on female reproductive function.
(© 2025. The Author(s).)

Declarations. Ethics approval and consent to participate: All patients enrolled in the study provided written informed consent to participate. This study was conducted in accordance with the principles of the Declaration of Helsinki. The study protocol was authorized by the Ethics Committee of the Unidade Local de Saúde de Santo António (ULSSA) / Instituto de Ciências Biomédicas Abel Salazar (ICBAS) [2020.119(097-DEFI/099-CE)]. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. Disclosure: All authors declare no conflicts of interest. The funding institutions had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Clinical trial number: Not applicable.

Clin Obstet Gynecol. 2021 Mar 1;64(1):3-11. (PMID: 32701517)
J Clin Med. 2023 Aug 02;12(15):. (PMID: 37568475)
Mol Cell Endocrinol. 2025 May 15;602:112536. (PMID: 40185328)
J Clin Endocrinol Metab. 1997 Jul;82(7):2248-56. (PMID: 9215302)
Front Endocrinol (Lausanne). 2023 Jul 17;14:1130211. (PMID: 37529616)
Hum Reprod. 2004 Jan;19(1):41-7. (PMID: 14688154)
Obes Manag. 2007 Apr;3(2):69-73. (PMID: 20436797)
Eur J Endocrinol. 2025 Mar 27;192(4):R29-R43. (PMID: 40186490)
J Reprod Infertil. 2024 Apr-Jun;25(2):102-109. (PMID: 39157800)
JBRA Assist Reprod. 2024 Dec 03;28(4):597-603. (PMID: 39311652)
Front Cell Dev Biol. 2024 Jul 01;12:1408879. (PMID: 39011395)
N Engl J Med. 2016 Aug 11;375(6):523-33. (PMID: 27509101)
JBRA Assist Reprod. 2025 Feb 21;:. (PMID: 39983029)
Diagnostics (Basel). 2022 Sep 25;12(10):. (PMID: 36292002)
Diabetes Care. 2014;37(5):1296-303. (PMID: 24561392)
Reprod Biol Endocrinol. 2023 Aug 1;21(1):70. (PMID: 37528417)
Mol Metab. 2020 May;35:100937. (PMID: 32244180)
Curr Obes Rep. 2024 Sep;13(3):584-595. (PMID: 38958869)
Curr Opin Endocrinol Diabetes Obes. 2012 Apr;19(2):81-7. (PMID: 22327367)
Ther Adv Endocrinol Metab. 2020 Jun 24;11:2042018820934319. (PMID: 32637065)
Biomedicines. 2023 Nov 27;11(12):. (PMID: 38137371)
Diabetes Metab Res Rev. 2023 Feb;39(2):e3599. (PMID: 36484476)
Hum Reprod. 2021 Aug 18;36(9):2463-2472. (PMID: 34223890)
Fertil Steril. 2018 Feb;109(2):324-329. (PMID: 29338857)
Reprod Biomed Online. 2021 Mar;42(3):529-545. (PMID: 33384269)
Diabetes Res Clin Pract. 2019 Jun;152:39-52. (PMID: 31063851)
Front Endocrinol (Lausanne). 2021 Jan 19;11:615957. (PMID: 33542709)
Int J Womens Health. 2023 Feb 05;15:151-166. (PMID: 36778752)
Reprod Biol Endocrinol. 2025 Jan 6;23(1):2. (PMID: 39762910)
Reprod Biomed Online. 2012 Jan;24(1):6-22. (PMID: 22133908)
J Pers Med. 2023 Aug 28;13(9):. (PMID: 37763087)
J Assist Reprod Genet. 2023 Jun;40(6):1437-1445. (PMID: 37212942)
J Endocr Soc. 2024 Jan 09;8(2):bvad169. (PMID: 38213910)
Am J Obstet Gynecol. 2014 Aug;211(2):163.e1-6. (PMID: 24657792)
Clin Med Insights Reprod Health. 2019 Sep 09;13:1179558119874042. (PMID: 31523137)
BMC Womens Health. 2022 Nov 28;22(1):479. (PMID: 36443765)
Clin Endocrinol (Oxf). 2021 Oct;95(4):531-541. (PMID: 33460482)
Hum Reprod Update. 2012 Nov-Dec;18(6):618-37. (PMID: 22767467)
Front Endocrinol (Lausanne). 2021 Oct 20;12:741764. (PMID: 34745009)
F S Rep. 2022 Dec 02;4(1):77-84. (PMID: 36959962)
J Clin Med. 2023 Feb 11;12(4):. (PMID: 36835989)
Endocr Rev. 2024 Mar 4;45(2):171-189. (PMID: 37559411)
Hum Reprod. 2014 Sep;29(9):1842-5. (PMID: 25008235)
BMC Womens Health. 2024 Apr 5;24(1):221. (PMID: 38580996)

Keywords: Body mass index; Fertility outcomes; Hormone profile; In vitro fertilization; Obesity; Overweight; Polycystic ovary syndrome

9002-67-9 (Luteinizing Hormone)

Date Created: 20250707 Date Completed: 20250708 Latest Revision: 20250710

20260130

PMC12232814

10.1186/s12958-025-01434-8

40624700